Defeating brain cancer requires a delicate balance. At least that’s how Dr. David Stojdl sees it. On the one hand, Dr. Stojdl is engineering viruses that seek out tumour cells in the brain, infect them and flag them as dangerous — yet don’t infect healthy cells. “Brain tissue is not very amenable to… Read more »
Tag: Dave Stojdl
World-first clinical trial for oncolytic virus immunotherapy featured by The National
Last night, CBC TV’s The National introduced its audience to a novel clinical trial currently underway in Canada. The trial has been partially enabled by support from BioCanRx to manufacture the engineered viruses being given to the study’s participants. The clinical trial is testing a new investigational therapy called oncolytic virus immunotherapy, which… Read more »
BioCanRx investigators receive $5M to develop virus therapy for prostate cancer
News item Prostate Cancer Canada and the Movember Foundation have partnered to award $5 million to 2020 to a multi-disciplinary team of scientists and clinicians led by BioCanRx Scientific Director, Dr. John Bell. The team is mainly composed of BioCanRx network investigators who are working together to develop a treatment specifically for prostate cancer… Read more »
